MedPageToday
MedPage Today) — Adding an anthracycline to adjuvant chemotherapy for TOP2A-normal early breast cancer significantly improved disease-free survival (DFS) but not overall survival (OS) at 10 years, and doubled the risk of heart failure, a randomized…
Read More
Small Benefit, Persistent Toxic Risk With Adjuvant Anthracycline in Breast Cancer
Gaylene Schroeder
13:27
MedPage Today) — Adding an anthracycline to adjuvant chemotherapy for TOP2A-normal early breast cancer significantly improved disease-free survival (DFS) but not overall survival (OS) at 10 years, and doubled the risk of heart failure, a randomized…
